Antiplatelet therapy for patients undergoing coronary artery bypass surgery.

Antiplatelet therapy for patients undergoing coronary artery bypass surgery. Kardiol Pol. 2018 May 21;: Authors: DeStephan CM, Schneider DJ Abstract Considerable variation in the use and duration of antiplatelet medications during the perioperative and postoperative care of patients undergoing coronary artery bypass grafting (CABG) reflects limited studies focused directly on these patients as well as variation in the results reported. In this review we will highlight the incidence and mechanisms of graft closure as well as the evidence in support of antiplatelet therapy that is balanced by the impact of antiplatelet therapy on the risk of bleeding to provide recommendations for the use of antiplatelet therapy in patients undergoing CABG. Low dose acetylsalicylic acid (ASA; ≤ 160 mg daily) reduces the incidence of perioperative myocardial infarction (MI), acute renal injury, and mortality without increasing the risk of bleeding and so is recommended both before and after CABG. The use of dual antiplatelet therapy with ASA plus a P2Y₁₂ antagonist adds a greater risk of bleeding. While additional studies are required, we can make the following recommendations: Because of increased bleeding and mortality when patients are treated with clopidogrel preoperatively, CABG should be delayed five days. Because of increased bleeding when patients are treated with ticagrelor preoperatively, CABG should be delayed three days. Because of inc...
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research